Review ArticlesHallucinations: diagnosis, neurobiology and clinical managementTang, Siu Waa,,b; Tang, Wayne HansbAuthor Information aDepartment of Psychiatry, University of California, Irvine, California, USA bInstitute of Brain Medicine, Hong Kong Received 13 December 2019 Accepted 5 March 2020 Correspondence to Siu W. Tang, MD, PhD, Department of Psychiatry, University of California, North Campus Psychiatry Trailer, Zot 1681 Irvine, CA 92697-1681, USA, Tel: + 1 949 824 3557; e-mail: [email protected] International Clinical Psychopharmacology: November 2020 - Volume 35 - Issue 6 - p 293-299 doi: 10.1097/YIC.0000000000000313 Buy Metrics Abstract Hallucinations are important diagnostic symptoms in schizophrenia, but also occur in other medical and neuropsychiatric conditions. Not all patients with hallucinations are psychotic. There has been a surge of interest in the topic of hallucinations, as new research data have begun to reveal their neurobiology. Hallucinogenic molecules may also serve as new scaffolds for the development of new psychotropic drugs. We searched and reviewed recent literature, focusing on the refinement of clinical management, which was inspired by new data regarding the neurobiology of hallucination subtypes. We concluded that the successful management of hallucinations depends on accurate differential diagnosis to identify subtypes, which would then determine the most appropriate treatment. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.